May 10, 2017 / 12:20 PM / 3 months ago

BRIEF-Aevi Genomic Medicine posts Q1 loss per share $0.29

May 10 (Reuters) - Aevi Genomic Medicine Inc

* Aevi Genomic Medicine announces plans to initiate Phase 2 clinical trial to confirm genetic responders to AEVI-001 and first quarter 2017 operating results

* Q1 loss per share $0.29

* Q1 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S

* Aevi Genomic Medicine Inc - patient recruitment for AEVI-002 in severe pediatric onset crohn's disease to begin during 2Q 2017

* Aevi Genomic Medicine - expect to initiate Phase 2 trial of AEVI-001 in patients with identified genetic subset during second half of 2017

* Aevi Genomic Medicine Inc - expects its reported cash balance to fund operations through end of q2 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below